✉news WorldUS Politics first seen 5 h ago, last 1 h ago, peak #12
Rezpegaldesleukin Shows Long-term Benefits in Alopecia Areata and Eczema
Original: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
New data on rezpegaldesleukin, an immunotherapy developed by Nektar Therapeutics, will be presented at the EADV Congress 2026, showing long-term durability of response and disease improvement in patients with alopecia areata and atopic dermatitis. The findings support the drug's potential as a durable treatment for these chronic immune-mediated skin conditions, and investors and dermatology specialists are following the data closely.
Why now: Positive late-stage clinical data for an experimental autoimmune drug is being presented at a major European dermatology conference.
RezpegaldesleukinNektar TherapeuticsEADV Congress 2026alopecia areataatopic dermatitis
Rank over time, top of the chart is #1. 4 snapshots from 5 h ago to 1 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/618360